Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

VRTX

Market Cap$121.6B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Vertex Pharmaceuticals, Inc.Vertex Pharmaceuticals, Inc.-248.2--2%11.8-

Earnings Call Q2 2024

August 1, 2024 - AI Summary

Vertex Pharmaceuticals reported strong financial results for the second quarter of 2024, with revenue increasing by 6% year-over-year to $2.65 billion.
The company raised its full-year product revenue guidance to a range of $10.65 billion to $10.85 billion, representing 9% growth at the midpoint.
Vertex continues to see strong demand for its cystic fibrosis (CF) treatments, reaching more patients and expanding into younger age groups. The upcoming launch of the Vanzacaftor Triple combination is expected to drive further growth in CF.

Exclusive for Stockcircle Pro members

Sign upSign Up
$531.00

Target Price by Analysts

12.7% upsideVertex Pharmaceuticals Target Price DetailsTarget Price
$698.90

Current Fair Value

48.3% upside

Undervalued by 48.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$121.60 Billion
Enterprise Value$122.53 Billion
Dividend Yield$0 (0%)
Earnings per Share$14.05
Beta0.4
Outstanding Shares258,100,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-248.21
PEG50.4
Price to Sales11.78
Price to Book Ratio7.85
Enterprise Value to Revenue11.86
Enterprise Value to EBIT-320.93
Enterprise Value to Net Income-251
Total Debt to Enterprise0.01
Debt to Equity0.05

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Vertex Pharmaceuticals, Inc.

CEO: Jeffrey Leiden